Release Date: 18 July 2024
Leqembi (lecanemab), a groundbreaking monoclonal antibody targeting amyloid beta, has revolutionized Alzheimer’s disease treatment. Developed through a collaboration between Bioarctic Neuroscience, Eisai, and Biogen...
Release Date: 17 July 2024
Developed on Regeneron’s VelociBi bispecific development platform, Ubamatamab (REGN4018) is a bispecific antibody designed to target MUC16 and CD3. With ongoing clinical trials for various gynecological cancers show...
Release Date: 17 July 2024
Sabestomig (AZD-7789) is at the forefront of revolutionizing classical Hodgkin lymphoma (cHL) treatment. Despite the substantial response rates of PD-1/PD-L1 pathway immunotherapies in relapsed/refractory cHL patients, th...
Release Date: 17 July 2024
Merus developed MCLA-158 (Petosemtamab), a Biclonics bispecific antibody targeting EGFR and LGR5 for the treatment of solid tumors characterized by EGFR and LGR5 overexpression. MCLA-158, as a first-in-class candidate tar...
Release Date: 17 July 2024
NVG-111 is a first-in-class bispecific T cell engager (TCE) antibody that targets tumors expressing ROR1 (Receptor Tyrosine Kinase like Orphan like Receptor 1) and is meant to kill cancer cells while without depleting normal B cells. It was based on ...
Release Date: 17 July 2024
Nivatrotamab, a groundbreaking bispecific anti-GD2 antibody, emerges as a potential game-changer in cancer therapeutics. Conceived by investigators at Memorial Sloan Kettering Cancer Center (MSKCC) and exclusively license...
Release Date: 17 July 2024
IPH6101/SAR443579, a novel NK cell engager developed jointly by Innate Pharma and Sanofi through a research collaboration and license agreement, marks a pioneering leap in cancer therapy. This unique multi-specific antibo...
Release Date: 17 July 2024
T cell engagers are emerging as a promising focus in autoimmune disease research, with Imvotamab (IGM-2323) leading the charge as a potent CD20xCD3 bispecific monoclonal antibody from IGM Biosciences. This innovative ther...
Release Date: 17 July 2024
IMM2902 is a first-in-class bispecific antibody-receptor fusion protein produced by ImmuneOnco Biopharmaceuticals in Shanghai that targets human CD47 and HER2. It is the company’s third CD47-based novel medicine con...
Release Date: 16 July 2024
Leads Biolabs ventured into the groundbreaking territory with the development of LBL-034, a GPRC5DxCD3 bispecific antibody designed specifically for the treatment of multiple myeloma. The choice of G protein-coupled recep...
Release Date: 16 July 2024
Genmab’s invention of DuoBody-CD3xCD30 (GEN3017) represents a paradigm shift in the pursuit of more effective and accurate hematological cancer treatment. GEN3017, based on Genmab’s DuoBody technology, binds t...
Release Date: 16 July 2024
As the world’s first recombinant humanized bispecific antibody, Erfonrilimab (KN046) is specially designed to target both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4). T...
Release Date: 16 July 2024
In the realm of cancer immunology, Exlinkibart has emerged as a promised contender, serving as a next-generation agonistic monoclonal antibody against CD137. The focus on CD137, a co-stimulatory receptor on T cells, under...
Release Date: 16 July 2024
EMB-02, a tetravalent PD-1xLAG-3 bispecific antibody created on EpimAb Biotherapeutics’ proprietary Fabs-In-Tandem-Immunoglobulin (FIT-Igandreg;) technology, appears as a ray of hope in the field of cancer treatment...
Release Date: 16 July 2024
The landscape of cancer treatment has witnessed a transformative shift with the advent of bispecific antibodies. These innovative therapeutics play a pivotal role in harnessing the power of the immune system against cance...